PETALING JAYA: Duopharma Biotech Bhd
’s earnings prospects are expected to be supported by improved market penetration and growing demand in key Asean markets along with the recent reduction in the overnight policy rate.
For the third quarter ended Sept 30, 2025 (3Q25), the group’s net profit surged by 45% year-on-year (y-o-y) to RM22.6mil or earnings per share of 2.35 sen. Revenue for 3Q25 grew by 7% y-o-y to RM222.5mil
For the nine-month period ended Sept 30, 2025 (9M25), the group’s net profit recorded an increase of 44% y-o-y to RM68.4mil or an earnings per share of 7.11 sen. This was mainly attributable to higher sales coupled with continued favourable active pharmaceutical ingredient costs and foreign exchange, which collectively reinforced profitability.
Revenue for 9M25 also increased by 14% y-o-y to RM707mil, primarily driven by sustained demand from both the public and private sectors across all business segments, including the additional contribution from a one-off surge in insulin supply during the first half of the year following supply normalisation.
Separately, the company announced that Datuk Arham Abdul Rahman has been redesignated from independent non-executive director to senior independent non-executive director.
The group also announced the retirement of independent and non-executive director Datuk Eisah A. Rahman.
